CJC-1295 DAC vs no DAC is first an identity question. A supplier’s alias is not enough to establish that two products are the same molecule or share a pharmacokinetic profile. Before repeating a long half-life, match the sequence, modifications and actual material to the intervention in the cited publication.
What the long-acting human study evaluated
The 2006 CJC-1295 report describes two randomized, placebo-controlled studies in healthy adults. It evaluated a long-acting GHRH analogue, measuring pharmacokinetics and GH and IGF-I responses. The abstract reports an estimated half-life of 5.8–8.1 days for the studied intervention.
That number belongs to that molecule and study. It is not a default value for every material with CJC-1295 in its retail name. A change in a molecular modification can change the evidence question.
What “no DAC” should prompt you to verify
When a label uses a shortened alias, ask for the complete material specification. Does it describe the same sequence and chemical modifications as the cited intervention? Does the analytical record test the expected identity? If the specification differs or is unclear, the published half-life should not be copied across.
Scroll horizontally to read all columns.
| Record field | Why it matters |
|---|---|
| Full sequence | Defines the amino-acid order |
| Modifications and conjugation | Can be part of the long-acting design |
| Salt and material specification | Clarifies what the labelled mass represents |
| Identity result | Tests a defined expected material |
| Study intervention | Determines which pharmacokinetic findings apply |
The manufacturer’s peptide documentation FAQs provide useful background on material specification and analytical terminology. They do not independently authenticate an unrelated seller’s product.
Hormone responses are not every hoped-for outcome
The study measured endocrine responses. It did not establish a universal result for muscle growth, injury recovery or healthy aging. A change in GH or IGF-I is an intermediate observation and should not be presented as a complete clinical benefit.
Our half-life versus duration guide explains why a pharmacokinetic number is also different from a duration of benefit. These concepts should not be merged into a product recommendation.
Short-term tolerability has a defined scope
Selected healthy volunteers and short observation periods do not characterize every long-term risk or population. A statement that no serious reactions were observed in that experiment is not a blanket safety assurance for online products or combinations.
Health Canada’s current overview identifies CJC-1295 in the context of unauthorized products promoted for human use. Molecular research does not replace Canadian product status.
Where to continue the comparison
Read the CJC-1295 dossier for the study context and GHRH versus GHRP for pathway terminology. If two materials cannot be matched to the same molecular specification, keep them separate rather than using one alias to erase the uncertainty. This article does not provide a dosing or preparation protocol.
